As part of its efforts to bolster Europe’s readiness for health emergencies, the European Commission wants to make sure that additional production capacity is available at short notice.
Pharmaceutical companies in the EU are to be invited to offer up part of their manufacturing capacity for the production of new vaccines and therapeutics in the event of a future health emergency, such as another pandemic.
The European Commission is setting up the “EU FAB” flexible manufacturing project, which it describes as a network of “ever-warm single and/or multi-technology production capacities” that will allow
European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.
Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.
